SCHEMBL22093357

SCHEMBL22093357

O=c1[nH]c(=O)n(-c2ccccc2Cl)c2cc(C(F)(F)F)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 4/20 0.50
▸ NFKB1 P19838 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ KCNMA1 Q12791 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ TNKS O95271 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ JUN P05412 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29570139 1.00 HSP90AA1 (0.50) HSP90AA1NFKB1MEN1CYP1A2CYP3A4
SCHEMBL31145530 0.90 MAT2A (0.42) HSP90AA1NFKB1MEN1CYP1A2CYP3A4
SCHEMBL22093346 0.90 MAT2A (0.42) HSP90AA1NFKB1MEN1CYP1A2CYP3A4
SCHEMBL22093088 0.85 HSP90AA1 (0.50) HSP90AA1NFKB1MEN1CYP1A2CYP3A4
SCHEMBL29569908 0.85 HSP90AA1 (0.50) HSP90AA1NFKB1MEN1CYP1A2CYP3A4
SCHEMBL22093538 0.83 MAT2A (0.55) HSP90AA1MEN1MAPTKMT2AMAT2A
SCHEMBL31145445 0.83 MAT2A (0.55) HSP90AA1MEN1MAPTKMT2AMAT2A
SCHEMBL22093310 0.82 ADORA3 (0.38) HSP90AA1MEN1CYP3A4MAPTCYP2C9
SCHEMBL31145507 0.82 BCAT2 (0.40) HSP90AA1MEN1MAPTTSHRKMT2A
SCHEMBL22093228 0.82 BCAT2 (0.40) HSP90AA1MEN1MAPTTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 — — US disclosed
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-05-30 — — US disclosed
US-20240108626-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-04-04 — — US disclosed
WO-2022256806-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. (US) 2022-12-08 — — WO disclosed
WO-2022256808-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR IDEAYA BIOSCIENCES INC. (US) 2022-12-08 — — WO disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 — — US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 — — EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 — — US disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 — — US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 — — US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 — — CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 — — US disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 — — US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 — — WO disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HSP90AA1 1827/4885NFKB1 3572/4885MEN1 1381/4885
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR PRMT1, PRMT6, MAT2A HSP90AA1 2211/4885NFKB1 4379/4885MEN1 492/4885
US-20240108626-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR PRMT1, PRMT6, MAT2A HSP90AA1 2211/4885NFKB1 4379/4885MEN1 492/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HSP90AA1 1827/4885NFKB1 3572/4885MEN1 1381/4885
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HSP90AA1 1827/4885NFKB1 3572/4885MEN1 1381/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A HSP90AA1 1827/4885NFKB1 3572/4885MEN1 1381/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HSP90AA1 1827/4885NFKB1 3572/4885MEN1 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback